Sigilon Therapeutics, Inc. financial data

Industry
Pharmaceutical Preparations
Location
100 Binney Street, Ste 600, Cambridge, MA
State of incorporation
Delaware
Fiscal year end
December 31

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 228 % -29.3%
Debt-to-equity 118 % +32.4%
Return On Equity -83.9 % +8.94%
Return On Assets -38.6 % +21%
Operating Margin -175 % +73%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.51M shares -92.2%
Common Stock, Shares, Outstanding 2.5M shares -92.3%
Common Stock, Value, Issued 3K USD -90.6%
Weighted Average Number of Shares Outstanding, Basic 2.5M shares +0.39%
Weighted Average Number of Shares Outstanding, Diluted 2.5M shares +0.39%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 17.7M USD +76.8%
Research and Development Expense 29.4M USD -46.4%
General and Administrative Expense 19.1M USD -2.94%
Operating Income (Loss) -30.8M USD +52.2%
Nonoperating Income (Expense) 595K USD +77.1%
Net Income (Loss) Attributable to Parent -30.3M USD +54.2%
Earnings Per Share, Basic 1.62 USD/shares +47.9%
Earnings Per Share, Diluted 1.62 USD/shares +47.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.6M USD -43.2%
Marketable Securities, Current 15.3M USD -71.5%
Cash, Cash Equivalents, and Short-term Investments 34.9M USD -60.4%
Assets, Current 44.9M USD -51.3%
Property, Plant and Equipment, Net 2.59M USD -23.9%
Operating Lease, Right-of-Use Asset 7.06M USD -34.7%
Assets 55.6M USD -48.3%
Accounts Payable, Current 1.11M USD +5.61%
Liabilities, Current 25.2M USD -24.2%
Operating Lease, Liability, Noncurrent 2.87M USD -57.8%
Liabilities 28.1M USD -49.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -177K USD +68.2%
Retained Earnings (Accumulated Deficit) -272M USD -12.5%
Stockholders' Equity Attributable to Parent 27.4M USD -47%
Liabilities and Equity 55.6M USD -48.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.4M USD +41.5%
Net Cash Provided by (Used in) Financing Activities -1.64M USD -3521%
Net Cash Provided by (Used in) Investing Activities 12.2M USD
Common Stock, Shares Authorized 175M shares 0%
Common Stock, Shares, Issued 2.5M shares -92.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -806K USD +98.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 20.9M USD -41.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 550K USD +31%
Payments to Acquire Property, Plant, and Equipment 351K USD -11.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -29.9M USD +55.2%
Property, Plant and Equipment, Gross 7.16M USD -0.11%
Operating Lease, Liability, Current 4.52M USD +1.85%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares 0%
Additional Paid in Capital 299M USD +1.88%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.26M USD +6.4%
Share-based Payment Arrangement, Expense 5.46M USD -6.01%
Interest Expense 2.18M USD +6.72%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%